End-of-day quote
Ljubljana S.E.
18:00:00 2024-04-25 EDT
|
5-day change
|
1st Jan Change
|
125.5
EUR
|
+0.40%
|
|
-0.40%
|
+14.09%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,320
|
2,862
|
3,676
|
2,857
|
3,402
|
3,869
|
-
|
-
|
Enterprise Value (EV)
1 |
2,101
|
2,558
|
3,373
|
2,338
|
3,228
|
3,355
|
3,326
|
3,089
|
P/E ratio
|
9.47
x
|
9.86
x
|
11.9
x
|
7.87
x
|
10.8
x
|
11.6
x
|
11.1
x
|
10.6
x
|
Yield
|
4.37%
|
5.47%
|
4.24%
|
6.12%
|
6%
|
5.56%
|
5.83%
|
5.99%
|
Capitalization / Revenue
|
1.55
x
|
1.86
x
|
2.35
x
|
1.66
x
|
1.88
x
|
2.06
x
|
1.98
x
|
1.87
x
|
EV / Revenue
|
1.41
x
|
1.67
x
|
2.15
x
|
1.36
x
|
1.79
x
|
1.79
x
|
1.7
x
|
1.49
x
|
EV / EBITDA
|
5.45
x
|
5.09
x
|
7.27
x
|
4.78
x
|
6.4
x
|
6.47
x
|
6.13
x
|
5.63
x
|
EV / FCF
|
9.35
x
|
10.2
x
|
10.5
x
|
6.27
x
|
36.7
x
|
12.2
x
|
11.3
x
|
9.81
x
|
FCF Yield
|
10.7%
|
9.82%
|
9.49%
|
16%
|
2.73%
|
8.22%
|
8.83%
|
10.2%
|
Price to Book
|
1.44
x
|
1.64
x
|
2.02
x
|
1.41
x
|
1.65
x
|
1.8
x
|
1.69
x
|
-
|
Nbr of stocks (in thousands)
|
31,690
|
31,313
|
31,152
|
31,052
|
30,925
|
30,832
|
-
|
-
|
Reference price
2 |
73.20
|
91.40
|
118.0
|
92.00
|
110.0
|
125.5
|
125.5
|
125.5
|
Announcement Date
|
20-03-19
|
21-03-18
|
22-03-17
|
23-04-13
|
24-03-14
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,493
|
1,535
|
1,566
|
1,717
|
1,806
|
1,874
|
1,956
|
2,068
|
EBITDA
1 |
385.4
|
502.4
|
463.6
|
488.9
|
504.2
|
518.6
|
542.2
|
549.1
|
EBIT
1 |
274.2
|
390.7
|
354.8
|
381.2
|
399.6
|
406.9
|
420.5
|
435.6
|
Operating Margin
|
18.36%
|
25.46%
|
22.66%
|
22.2%
|
22.12%
|
21.71%
|
21.5%
|
21.06%
|
Earnings before Tax (EBT)
1 |
284.4
|
339
|
362.4
|
433.1
|
367.1
|
409
|
425.5
|
422.5
|
Net income
1 |
245.5
|
291
|
309.2
|
363.3
|
313.9
|
343.4
|
358.6
|
369.1
|
Net margin
|
16.44%
|
18.96%
|
19.75%
|
21.15%
|
17.38%
|
18.32%
|
18.34%
|
17.84%
|
EPS
2 |
7.730
|
9.270
|
9.920
|
11.69
|
10.14
|
10.81
|
11.31
|
11.82
|
Free Cash Flow
1 |
224.7
|
251.2
|
320.2
|
372.9
|
88.04
|
275.8
|
293.5
|
314.9
|
FCF margin
|
15.05%
|
16.36%
|
20.45%
|
21.71%
|
4.87%
|
14.71%
|
15.01%
|
15.22%
|
FCF Conversion (EBITDA)
|
58.3%
|
49.99%
|
69.06%
|
76.28%
|
17.46%
|
53.18%
|
54.14%
|
57.35%
|
FCF Conversion (Net income)
|
91.52%
|
86.31%
|
103.55%
|
102.65%
|
28.04%
|
80.31%
|
81.85%
|
85.32%
|
Dividend per Share
2 |
3.200
|
5.000
|
5.000
|
5.630
|
6.600
|
6.982
|
7.320
|
7.520
|
Announcement Date
|
20-03-19
|
21-03-18
|
22-03-17
|
23-04-13
|
24-03-14
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
219
|
304
|
303
|
519
|
174
|
515
|
543
|
781
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
225
|
251
|
320
|
373
|
88
|
276
|
294
|
315
|
ROE (net income / shareholders' equity)
|
15.2%
|
17.1%
|
17%
|
17.9%
|
14.5%
|
15.1%
|
14.9%
|
14.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
13%
|
13.9%
|
11.5%
|
11.7%
|
11.8%
|
11.3%
|
Assets
1 |
-
|
-
|
2,387
|
2,614
|
2,730
|
2,935
|
3,039
|
3,266
|
Book Value Per Share
2 |
50.90
|
55.80
|
58.50
|
65.20
|
66.50
|
69.80
|
74.20
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
111
|
80.8
|
72.1
|
94.7
|
139
|
144
|
144
|
143
|
Capex / Sales
|
7.41%
|
5.27%
|
4.61%
|
5.52%
|
7.71%
|
7.69%
|
7.35%
|
6.92%
|
Announcement Date
|
20-03-19
|
21-03-18
|
22-03-17
|
23-04-13
|
24-03-14
|
-
|
-
|
-
|
Last Close Price
125.5
EUR Average target price
133.6
EUR Spread / Average Target +6.49% Consensus |
1st Jan change
|
Capi.
|
---|
| +14.09% | 4.13B | | +19.62% | 43.34B | | +20.44% | 21.96B | | +10.86% | 14.09B | | +13.07% | 13.64B | | +37.46% | 11.43B | | -8.59% | 6.86B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +8.46% | 5.22B |
Generic Pharmaceuticals
|